NCT01450020 is a NA clinical trial of educational intervention in Breast Cancer, sponsored by City of Hope Medical Center.

Who is sponsoring NCT01450020?

NCT01450020 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT01450020?

Interventions in NCT01450020: educational intervention, questionnaire administration, counseling intervention, survey administration, quality-of-life assessment.

What condition does NCT01450020 study?

NCT01450020 studies Breast Cancer.

Is NCT01450020 still recruiting?

NCT01450020 is currently active, enrolled. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT01450020

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors

Active, enrolled NA Last updated 7 April 2026

What this trial tests

NA trial testing educational intervention in Breast Cancer in 145 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 June 2012

Primary endpoint
15 June 2026

15 June 2026

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	145
Start date	1 June 2012
Primary completion	15 June 2026
Estimated completion	15 June 2026
Sites	1 location across United States

Drugs / interventions tested

educational intervention
questionnaire administration
counseling intervention
survey administration
quality-of-life assessment

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

City of Hope Medical Center

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized clinical trial studies peer navigator education in improving survivorship care in African American breast cancer survivors. An educational intervention involving peer groups may help to improve the well-being and quality of life (QOL) in breast cancer survivors

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Follow-up strategies following completion of primary cancer treatment in adult cancer survivors.
Høeg BL, Bidstrup PE, Karlsen RV, Friberg AS, et al · · 2019 · cited 64× · PMID 31750936 · DOI 10.1002/14651858.cd012425.pub2

Verify or expand the search:

Other trials of educational intervention

Trials testing the same drug.

NCT06969482 — The Effect of Patient Advocacy Training on Advocacy Skills, Ethical Sensitivity, and Patient Safety Culture in Nurses · NA · not yet recruiting
NCT05976477 — Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older Patients · NA · unknown
NCT06323759 — Perinatal EDucation: Pedagogical Strategy and Facilitators for the PROMotion of BreastFeeding · NA · completed
NCT05832957 — The Effectiveness of Cognitive-Functional Intervention to Reduce Driving Risk Factors of Adolescents With ADHD · NA · completed
NCT05488743 — Smoking Prevention Program in Poland · unknown

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01450020 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01450020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing